126 related articles for article (PubMed ID: 20870432)
1. Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma.
Korytko TP; Lowe GJ; Jimenez RE; Pohar KS; Martin DD
Urol Oncol; 2012 Sep; 30(5):602-6. PubMed ID: 20870432
[TBL] [Abstract][Full Text] [Related]
2. Skene's gland adenocarcinoma resembling prostatic adenocarcinoma.
Pongtippan A; Malpica A; Levenback C; Deavers MT; Silva EG
Int J Gynecol Pathol; 2004 Jan; 23(1):71-4. PubMed ID: 14668555
[TBL] [Abstract][Full Text] [Related]
3. Skene's gland adenocarcinoma with increased serum level of prostate-specific antigen.
Dodson MK; Cliby WA; Keeney GL; Peterson MF; Podratz KC
Gynecol Oncol; 1994 Nov; 55(2):304-7. PubMed ID: 7525428
[TBL] [Abstract][Full Text] [Related]
4. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer.
Sheinbein C; Teh BS; Mai WY; Grant W; Paulino A; Butler EB
Urology; 2010 Sep; 76(3):728-33. PubMed ID: 19616279
[TBL] [Abstract][Full Text] [Related]
6. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
7. Skene's Gland Malignancy: A Case Report and Systematic Review.
Slopnick EA; Bagby C; Mahran A; Nagel C; Garcia J; El-Nashar S; Hijaz AK
Urology; 2022 Jul; 165():36-43. PubMed ID: 35192863
[TBL] [Abstract][Full Text] [Related]
8. Female urethral adenocarcinoma: evidence for more than one tissue of origin?
Dodson MK; Cliby WA; Pettavel PP; Keeney GL; Podratz KC
Gynecol Oncol; 1995 Dec; 59(3):352-7. PubMed ID: 8522254
[TBL] [Abstract][Full Text] [Related]
9. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
Martin JM; Rosewall T; Bayley A; Bristow R; Chung P; Crook J; Gospodarowicz M; McLean M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1084-9. PubMed ID: 17606331
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer.
Schaefer U; Micke O; Willich N
Anticancer Res; 1999; 19(4A):2645-8. PubMed ID: 10470211
[TBL] [Abstract][Full Text] [Related]
13. Female urethral carcinoma: evidences to origin from Skene's glands.
Reis LO; Billis A; Ferreira FT; Ikari LY; Stellini RF; Ferreira U
Urol Oncol; 2011; 29(2):218-23. PubMed ID: 19450996
[TBL] [Abstract][Full Text] [Related]
14. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
Ost P; Lumen N; Goessaert AS; Fonteyne V; De Troyer B; Jacobs F; De Meerleer G
Eur Urol; 2011 Oct; 60(4):842-9. PubMed ID: 21514039
[TBL] [Abstract][Full Text] [Related]
15. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
17. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy.
Schild SE; Buskirk SJ; Wong WW; Halyard MY; Swanson SK; Novicki DE; Ferrigni RG
J Urol; 1996 Nov; 156(5):1725-9. PubMed ID: 8863580
[TBL] [Abstract][Full Text] [Related]
18. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy for regionally localized hormone refractory prostate cancer.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):907-12. PubMed ID: 7591901
[TBL] [Abstract][Full Text] [Related]
20. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
